Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity, Inc. stock logo
CELC
Celcuity
$13.84
+2.2%
$12.16
$7.58
$19.77
$520.28M0.45270,494 shs109,221 shs
Enhabit, Inc. stock logo
EHAB
Enhabit
$6.73
+0.1%
$9.34
$6.50
$10.91
$340.81M1.72488,036 shs137,430 shs
InnovAge Holding Corp. stock logo
INNV
InnovAge
$3.86
+1.7%
$4.01
$2.60
$6.69
$520.60M0.5150,336 shs10,206 shs
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$2.80
-4.3%
$2.16
$1.37
$9.13
$105.29M0.99178,153 shs107,998 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity, Inc. stock logo
CELC
Celcuity
-0.37%-1.53%+16.72%+21.76%-21.64%
Enhabit, Inc. stock logo
EHAB
Enhabit
-1.40%-5.09%-27.66%-8.22%-29.45%
InnovAge Holding Corp. stock logo
INNV
InnovAge
-3.31%-11.83%-2.31%+37.68%-37.40%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
0.00%+5.80%+52.08%-16.09%-62.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Celcuity, Inc. stock logo
CELC
Celcuity
1.5264 of 5 stars
3.51.00.00.00.62.50.0
Enhabit, Inc. stock logo
EHAB
Enhabit
3.4706 of 5 stars
3.34.00.00.02.90.02.5
InnovAge Holding Corp. stock logo
INNV
InnovAge
1.6339 of 5 stars
2.82.00.00.01.91.70.6
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
0.2589 of 5 stars
0.02.00.00.00.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celcuity, Inc. stock logo
CELC
Celcuity
3.00
Buy$28.25104.10% Upside
Enhabit, Inc. stock logo
EHAB
Enhabit
2.50
Moderate Buy$8.7530.01% Upside
InnovAge Holding Corp. stock logo
INNV
InnovAge
1.50
Reduce$5.0029.40% Upside
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SERA, CELC, EHAB, and INNV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/30/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00
5/19/2025
Celcuity, Inc. stock logo
CELC
Celcuity
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
5/15/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$3.11 per shareN/A
Enhabit, Inc. stock logo
EHAB
Enhabit
$1.03B0.33$4.08 per share1.65$10.92 per share0.62
InnovAge Holding Corp. stock logo
INNV
InnovAge
$763.85M0.68N/AN/A$2.04 per share1.89
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$80K1,316.10N/AN/A$1.40 per share2.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celcuity, Inc. stock logo
CELC
Celcuity
-$111.78M-$3.03N/AN/AN/AN/A-96.21%-49.44%8/13/2025 (Estimated)
Enhabit, Inc. stock logo
EHAB
Enhabit
-$156.20M-$2.77N/A23.21N/A-13.43%2.02%0.94%8/6/2025 (Estimated)
InnovAge Holding Corp. stock logo
INNV
InnovAge
-$21.34M-$0.23N/A64.40N/A-3.75%-11.91%-5.85%9/9/2025 (Estimated)
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$32.90M-$0.94N/AN/AN/A-28,685.22%-51.35%-37.21%8/6/2025 (Estimated)

Latest SERA, CELC, EHAB, and INNV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Celcuity, Inc. stock logo
CELC
Celcuity
-$0.94N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Enhabit, Inc. stock logo
EHAB
Enhabit
$0.10N/AN/AN/A$263.39 millionN/A
8/6/2025Q2 2025
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$0.21N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Celcuity, Inc. stock logo
CELC
Celcuity
-$0.95-$0.86+$0.09-$0.86N/AN/A
5/14/2025Q1 2025
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$0.24-$0.20+$0.04-$0.20$0.06 million$0.04 million
5/7/2025Q1 2025
Enhabit, Inc. stock logo
EHAB
Enhabit
$0.07$0.10+$0.03$0.35$266.11 million$259.90 million
5/6/2025Q3 2025
InnovAge Holding Corp. stock logo
INNV
InnovAge
-$0.02-$0.08-$0.06-$0.08$214.09 million$218.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
Enhabit, Inc. stock logo
EHAB
Enhabit
N/AN/AN/AN/AN/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
N/AN/AN/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celcuity, Inc. stock logo
CELC
Celcuity
1.14
6.61
6.61
Enhabit, Inc. stock logo
EHAB
Enhabit
0.82
1.49
1.49
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.04
0.78
0.78
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/A
2.02
2.02

Institutional Ownership

CompanyInstitutional Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
Enhabit, Inc. stock logo
EHAB
Enhabit
N/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
12.26%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
54.64%

Insider Ownership

CompanyInsider Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
15.77%
Enhabit, Inc. stock logo
EHAB
Enhabit
3.40%
InnovAge Holding Corp. stock logo
INNV
InnovAge
1.40%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
15.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celcuity, Inc. stock logo
CELC
Celcuity
4037.87 million31.89 millionOptionable
Enhabit, Inc. stock logo
EHAB
Enhabit
10,70050.64 million48.92 millionOptionable
InnovAge Holding Corp. stock logo
INNV
InnovAge
2,350135.01 million133.12 millionOptionable
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
12037.67 million31.72 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celcuity stock logo

Celcuity NASDAQ:CELC

$13.84 +0.30 (+2.22%)
As of 02:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Enhabit stock logo

Enhabit NYSE:EHAB

$6.73 +0.01 (+0.15%)
As of 02:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas.

InnovAge stock logo

InnovAge NASDAQ:INNV

$3.86 +0.06 (+1.68%)
As of 02:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.

Sera Prognostics stock logo

Sera Prognostics NASDAQ:SERA

$2.80 -0.13 (-4.28%)
As of 02:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.